JP2020073564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020073564A5 JP2020073564A5 JP2020001832A JP2020001832A JP2020073564A5 JP 2020073564 A5 JP2020073564 A5 JP 2020073564A5 JP 2020001832 A JP2020001832 A JP 2020001832A JP 2020001832 A JP2020001832 A JP 2020001832A JP 2020073564 A5 JP2020073564 A5 JP 2020073564A5
- Authority
- JP
- Japan
- Prior art keywords
- indirubin
- composition
- average particle
- particle size
- effective average
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 claims 46
- 239000000203 mixture Substances 0.000 claims 25
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 claims 23
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 claims 23
- 239000002245 particle Substances 0.000 claims 18
- 239000003381 stabilizer Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 4
- 150000003868 ammonium compounds Chemical class 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001305 cysteine hydrochloride Drugs 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001804 emulsifying effect Effects 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- -1 fatty acid ester Chemical class 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000008297 liquid dosage form Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims 1
- 238000001238 wet grinding Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021118361A JP2021181447A (ja) | 2012-06-21 | 2021-07-19 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| JP2023021518A JP2023062070A (ja) | 2012-06-21 | 2023-02-15 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662469P | 2012-06-21 | 2012-06-21 | |
| US61/662,469 | 2012-06-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018144837A Division JP2018199685A (ja) | 2012-06-21 | 2018-08-01 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021118361A Division JP2021181447A (ja) | 2012-06-21 | 2021-07-19 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020073564A JP2020073564A (ja) | 2020-05-14 |
| JP2020073564A5 true JP2020073564A5 (enExample) | 2020-06-25 |
Family
ID=49769412
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015518599A Active JP6382187B2 (ja) | 2012-06-21 | 2013-06-21 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| JP2018144837A Pending JP2018199685A (ja) | 2012-06-21 | 2018-08-01 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| JP2020001832A Pending JP2020073564A (ja) | 2012-06-21 | 2020-01-09 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| JP2021118361A Pending JP2021181447A (ja) | 2012-06-21 | 2021-07-19 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| JP2023021518A Pending JP2023062070A (ja) | 2012-06-21 | 2023-02-15 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015518599A Active JP6382187B2 (ja) | 2012-06-21 | 2013-06-21 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| JP2018144837A Pending JP2018199685A (ja) | 2012-06-21 | 2018-08-01 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021118361A Pending JP2021181447A (ja) | 2012-06-21 | 2021-07-19 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| JP2023021518A Pending JP2023062070A (ja) | 2012-06-21 | 2023-02-15 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10039829B2 (enExample) |
| EP (2) | EP2863897B1 (enExample) |
| JP (5) | JP6382187B2 (enExample) |
| CN (2) | CN104602675B (enExample) |
| CA (1) | CA2914782C (enExample) |
| WO (1) | WO2013192493A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6382187B2 (ja) * | 2012-06-21 | 2018-08-29 | フォスフォレックス，インコーポレーテッド | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| JP2017500343A (ja) * | 2013-12-20 | 2017-01-05 | フォスフォレックス，インコーポレーテッド | インジルビン固体分散体組成物 |
| RU2630561C2 (ru) * | 2015-10-20 | 2017-09-11 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России | Способ получения водно-солевых дисперсий фуллерена |
| EP3600259A4 (en) * | 2017-03-29 | 2020-11-25 | Phosphorex, Inc. | NEW PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBINE AND DERIVATIVES THEREOF AND METHODS FOR THE MANUFACTURE AND USE OF THEM |
| RU2721318C1 (ru) * | 2019-02-28 | 2020-05-18 | Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" | Способ получения золей и суспензий |
| CA3136081A1 (en) * | 2019-05-03 | 2020-11-12 | Azora Therapeutics, Inc. | Compositions comprising indigo and/or an indigo derivative and methods of use thereof |
| CN114668744A (zh) * | 2022-03-23 | 2022-06-28 | 成都大学 | 一种靛玉红固体脂质纳米粒及其制备方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4929242A (en) * | 1986-11-26 | 1990-05-29 | Baxter International Inc. | Solution and method for maintaining patency of a catheter |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
| US7998507B2 (en) * | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
| DE10129028A1 (de) * | 2001-06-11 | 2003-01-02 | Schering Ag | Lösliche Cdk-inhibitorische Indirubinderivate |
| US20050154046A1 (en) | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| EP1458734B1 (en) * | 2001-12-13 | 2010-10-13 | Natrogen Therapeutics, Inc. | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
| DE60309300T3 (de) * | 2002-03-20 | 2011-02-24 | Elan Pharma International Ltd. | Nanopartikelzusammensetzungen von angiogeneseinhibitoren |
| US20080220074A1 (en) * | 2002-10-04 | 2008-09-11 | Elan Corporation Plc | Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same |
| DE602004024963D1 (de) * | 2003-03-13 | 2010-02-25 | Controlled Chemicals Inc | Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer |
| CN1615852A (zh) * | 2003-11-10 | 2005-05-18 | 许军 | 靛玉红口服滴丸及制备工艺 |
| KR100588803B1 (ko) * | 2004-01-27 | 2006-06-12 | 학교법인조선대학교 | 암세포주에 항암활성을 지닌 인디루빈 유도체 |
| UA89513C2 (uk) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
| JP2008524239A (ja) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミティド | ナノ粒子のタクロリムス製剤 |
| WO2006069098A1 (en) * | 2004-12-22 | 2006-06-29 | Elan Pharma International Ltd. | Nanoparticulate bicalutamide formulations |
| AU2006204083A1 (en) * | 2005-01-06 | 2006-07-13 | Elan Pharma International Ltd. | Nanoparticulate candesartan formulations |
| BRPI0608173A2 (pt) * | 2005-02-24 | 2010-11-09 | Elan Pharma Int Ltd | composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo |
| US20060204588A1 (en) * | 2005-03-10 | 2006-09-14 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof |
| EP1865928A1 (en) * | 2005-03-17 | 2007-12-19 | Elan Pharma International Limited | Nanoparticulate biphosphonate compositions |
| KR20070121786A (ko) * | 2005-03-23 | 2007-12-27 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 코르티코스테로이드 및 항히스타민 제제 |
| US7825087B2 (en) * | 2005-04-12 | 2010-11-02 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
| JP2008535924A (ja) * | 2005-04-12 | 2008-09-04 | エラン ファーマ インターナショナル リミテッド | ナノ粒子キナゾリン誘導体製剤 |
| WO2006130769A2 (en) | 2005-06-02 | 2006-12-07 | Tercica, Inc. | Methods for treatment of growth disorders |
| CN101023944A (zh) * | 2006-02-23 | 2007-08-29 | 黎明涛 | 靛玉红衍生物在制备治疗神经退行性变疾病药物中的应用 |
| CN101074229B (zh) * | 2007-06-08 | 2010-09-01 | 无锡杰西医药科技有限公司 | 7-氮杂靛玉红和7-氮杂异靛蓝衍生物制备及其药学用途 |
| EP2057982A1 (en) | 2007-11-09 | 2009-05-13 | Archimedes Development Limited | Intranasal compositions |
| WO2009117042A1 (en) * | 2008-03-21 | 2009-09-24 | Adlyfe, Inc. | Use of pyrene to carry non-peptide agents across the blood brain barrier |
| SI2113253T1 (sl) * | 2008-04-30 | 2010-06-30 | Immatics Biotechnologies Gmbh | Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva |
| CN101362066B (zh) * | 2008-09-27 | 2010-12-22 | 同济大学 | 脂质体包埋量子点的二氧化硅微球的制备方法及其产品 |
| CN101775082B (zh) * | 2010-02-09 | 2012-06-27 | 中国药科大学 | 基于两性离子的电荷反转型壳聚糖衍生物及其在药剂中的应用 |
| CN102018736B (zh) * | 2010-11-19 | 2012-03-28 | 成都中医药大学 | 一种青黛饮片及其制备方法 |
| CN102228433B (zh) * | 2011-06-29 | 2012-11-28 | 上海中医药大学 | 过饱和自微乳制剂及其制备方法和应用 |
| JP6382187B2 (ja) * | 2012-06-21 | 2018-08-29 | フォスフォレックス，インコーポレーテッド | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
-
2013
- 2013-06-21 JP JP2015518599A patent/JP6382187B2/ja active Active
- 2013-06-21 CN CN201380043697.4A patent/CN104602675B/zh active Active
- 2013-06-21 CA CA2914782A patent/CA2914782C/en active Active
- 2013-06-21 WO PCT/US2013/046981 patent/WO2013192493A1/en not_active Ceased
- 2013-06-21 EP EP13806153.6A patent/EP2863897B1/en active Active
- 2013-06-21 CN CN201910470369.1A patent/CN110123763A/zh active Pending
- 2013-06-21 EP EP19180122.4A patent/EP3597178A1/en not_active Withdrawn
-
2014
- 2014-12-17 US US14/573,212 patent/US10039829B2/en active Active
-
2018
- 2018-07-20 US US16/040,640 patent/US10675350B2/en active Active
- 2018-08-01 JP JP2018144837A patent/JP2018199685A/ja active Pending
-
2020
- 2020-01-09 JP JP2020001832A patent/JP2020073564A/ja active Pending
-
2021
- 2021-07-19 JP JP2021118361A patent/JP2021181447A/ja active Pending
- 2021-09-09 US US17/470,163 patent/US20220168423A1/en not_active Abandoned
-
2023
- 2023-02-15 JP JP2023021518A patent/JP2023062070A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020073564A5 (enExample) | ||
| Jacob et al. | Emerging role of nanosuspensions in drug delivery systems | |
| JP4623966B2 (ja) | 表面安定剤としてチロキサポールを含有する、濾過滅菌したブデソニドおよびベクロメタゾンのナノ粒子製剤 | |
| EP3513809B1 (en) | Medicinal composition comprising tivozanib | |
| EP3390367B1 (en) | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation | |
| JP2010111685A (ja) | 表面安定剤として共重合体を含むナノ粒子組成物 | |
| JP2012521412A (ja) | 鼻のアレルギー疾患において適用するためのクルクミノイドおよびその代謝物 | |
| JP2013514373A (ja) | 非刺激性の眼科用ポビドンヨード組成物 | |
| JP5604395B2 (ja) | マイクロエマルジョンおよび気道疾患を防ぐためのその使用 | |
| ES2884849T3 (es) | Composiciones de profármaco de aripiprazol | |
| US10251866B2 (en) | Pharmaceutical nanosuspension | |
| WO2020034989A1 (zh) | 一种可注射的药物组合物及其制备方法 | |
| Liu | Nanocrystal formulation for poorly soluble drugs | |
| Garg et al. | Current nanotechnological approaches for an effective delivery of bioactive drug molecules to overcome drug resistance tuberculosis | |
| JP2015520241A5 (enExample) | ||
| LU102486A1 (en) | Cannabidiol nanocrystal compositions | |
| JP2012505236A (ja) | コルチコステロイド組成物およびそれの治療方法 | |
| JP2017527600A5 (enExample) | ||
| ES2893973T3 (es) | Composiciones de múltiples profármacos de aripiprazol | |
| Lu | Recent advances in developing ophthalmic formulations: a patent review | |
| JPH1192368A (ja) | ベンゾピラン誘導体を主成分とする水性液剤 | |
| JP2019533008A5 (enExample) | ||
| JP2019531344A5 (enExample) | ||
| ES2721270T5 (es) | Composiciones de profármaco de aripiprazol | |
| US10201552B2 (en) | Method of increasing the bioavailability of an HIV drug |